Q1 2019 Earnings Estimate for Diplomat Pharmacy Inc (DPLO) Issued By William Blair
Diplomat Pharmacy Inc (NYSE:DPLO) – Equities research analysts at William Blair lowered their Q1 2019 earnings estimates for shares of Diplomat Pharmacy in a report released on Saturday. William Blair analyst J. Kreger now forecasts that the company will post earnings of $0.38 per share for the quarter, down from their prior estimate of $0.40. William Blair also issued estimates for Diplomat Pharmacy’s Q2 2019 earnings at $0.35 EPS, Q3 2019 earnings at $0.39 EPS and Q4 2019 earnings at $0.40 EPS.
A number of other research firms also recently issued reports on DPLO. Mizuho boosted their target price on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “neutral” rating in a research report on Tuesday, November 7th. Needham & Company LLC boosted their target price on shares of Diplomat Pharmacy from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Monday. Leerink Swann boosted their target price on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “market perform” rating in a research report on Tuesday, November 7th. BidaskClub upgraded shares of Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 5th. Finally, Zacks Investment Research upgraded shares of Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 target price on the stock in a research report on Tuesday, October 10th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $20.94.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.25 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the firm posted $0.21 EPS. The company’s quarterly revenue was down 4.8% on a year-over-year basis.
In other Diplomat Pharmacy news, Director Jeffrey G. Park acquired 3,000 shares of the stock in a transaction on Monday, November 20th. The shares were purchased at an average price of $15.46 per share, for a total transaction of $46,380.00. Following the completion of the acquisition, the director now owns 7,640 shares in the company, valued at approximately $118,114.40. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, President Joel Saban acquired 10,000 shares of the stock in a transaction on Monday, November 20th. The shares were acquired at an average price of $15.24 per share, for a total transaction of $152,400.00. Following the acquisition, the president now owns 12,000 shares of the company’s stock, valued at approximately $182,880. The disclosure for this purchase can be found here. Insiders have purchased a total of 15,000 shares of company stock worth $228,780 in the last quarter. 30.20% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio raised its holdings in Diplomat Pharmacy by 3,847.7% during the third quarter. Public Employees Retirement System of Ohio now owns 42,359 shares of the company’s stock worth $877,000 after buying an additional 41,286 shares during the last quarter. Sterling Capital Management LLC acquired a new position in Diplomat Pharmacy during the third quarter worth $2,283,000. Piedmont Investment Advisors LLC acquired a new position in Diplomat Pharmacy during the third quarter worth $216,000. Continental Advisors LLC raised its holdings in Diplomat Pharmacy by 30.5% during the third quarter. Continental Advisors LLC now owns 42,800 shares of the company’s stock worth $886,000 after buying an additional 10,000 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Diplomat Pharmacy during the third quarter worth $8,226,000. Hedge funds and other institutional investors own 72.21% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Q1 2019 Earnings Estimate for Diplomat Pharmacy Inc (DPLO) Issued By William Blair” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2018/01/11/q1-2019-earnings-estimate-for-diplomat-pharmacy-inc-dplo-issued-by-william-blair.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.